

CHAIRS: **F. Kirchhoff** (Ulm, Germany, EU) **D. Margolis** (Chapel Hill, North Carolina, USA)

Denver, Colorado March 4th, 2024 h 06.00 - 07.30 pm



16th NATIONAL CONGRESS Italian Conference on AIDS and Antiviral Research JUNE 19-21 ROME, ITALY

CRO ³¹* CONFERENCE ON Retroviruses and Opportunistic Infections MARCH 3-6 2024 DENVER, COLORADO








CHAIRS: F. Kirchhoff (Ulm, Germany, EU), D. Margolis (Chapel Hill, North Carolina, USA)

SARS-CoV-2 Infection and Hospitalization in Immunocompromised Children: A Population-Based Study

Costanza Di Chiara, Giugni A., Le Prevost M., Boracchini R., Barbieri E., Lupattelli A., Giaquinto C., Donà D.#, Cantarutti A.

on behalf of the VERDI study team








Background

Conflicting evidence exists on COVID-19 incidence and severity in immunocompromised (IC) children

- ?
- What is the risk of SARS-CoV-2 infection in IC kids?
 - Is IC status a risk factor for severe COVID-19 in kids?





To assess the incidence and severity of SARS-CoV-2 infection in immunocompromised children.

We evaluated the risk of:

- SARS-CoV-2 primary infection
- COVID-19-related hospitalization
- Severe COVID-19 outcomes

in children with or without an immunocompromising status





Study design and methods

Study design and Data Sources

- Population-based cohort study
- Real-world data from electronic medical registries in Italy and Norway
- Children aged 0-18 years
- Data collected from February 2020 to February 2022






Study design and methods

Definitions


- Severe COVID-19: ICU admission, and/or ventilation or hemodynamic support need, and/or death
- Participants were classified into three groups:

IC: Immunocompromised children (see table) non-IC: Children with specific non-immunocompromising underlying conditions recognized as risk factors for severe pediatric COVID-19 (e.g., diabetes, obesity, etc) RC: Reference children (i.e., neither IC nor non-IC)






Results – cohorts' characteristics



Results – Risk of SARS-CoV-2 infection

■ Italy ■ Norway

IC children showed comparable or lower risk of SARS-CoV-2 infection to immunocompetent children




Risk of SARS-CoV-2 primary infection

Models were adjusted for several potential confounders (age, gender, deprivation index, number of visits and antibiotic prescriptions). COVID-19 vaccination was considered as a competing event in our analysis.



Results – Risk of hospitalization

IC children had a **4-11-fold higher risk of hospitalization** compared to immunocompetent children without other risk factors, regardless of infection severity



Zero and five cases developed severe COVID-19 in Italy and Norway, respectively.





Conclusions

- Data from Italy and Norway are in general comparable
- IC children showed a comparable / lower risk of SARS-CoV-2 primary infection but a higher risk of hospitalization compared to both non-IC and RC
- Notably, severe COVID-19 cases were very rare in both datasets
- Lower risk of infection IC may be related to a reduced exposure (e.g. higher isolation measures) and/or higher vaccine acceptance
- Higher hospitalization rate in IC may be due to lower admission thresholds
- The higher risk of hospitalization in IC did not translate into higher rate of COVID-19 severity.





Acknowledgments





This work is part of the VERDI project (grant no. 101045989), which is funded by the European Union.

Thank you!

costanza.dichiara@unipd.it







